FigureĀ 3.
MCL-1 and BCL-xL PD data. MCL-1 and BCL-xL were assessed by flow cytometry in blood at C1D1, C1D5 pretreatment, and C1D15 pretreatment. Ven-idasa treatment resulted in modest decreases in MCL-1, and to a lesser degree BCL-xL, that trend with dose and response. Groups by treatment include patients who received indicated idasa dose, regardless of ven dose received. D, day; MFI, mean fluorescence intensity; ND, no data; PD, progressive disease; PR, partial response; RD, refractory disease; SD, stable disease.

MCL-1 and BCL-xL PD data. MCL-1 and BCL-xL were assessed by flow cytometry in blood at C1D1, C1D5 pretreatment, and C1D15 pretreatment. Ven-idasa treatment resulted in modest decreases in MCL-1, and to a lesser degree BCL-xL, that trend with dose and response. Groups by treatment include patients who received indicated idasa dose, regardless of ven dose received. D, day; MFI, mean fluorescence intensity; ND, no data; PD, progressive disease; PR, partial response; RD, refractory disease; SD, stable disease.

Close Modal

or Create an Account

Close Modal
Close Modal